Gain Therapeutics (NASDAQ:GANX) Earns "Buy" Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX - Free Report) in a research note published on Monday morning,Benzinga reports. The firm currently has a $8.00 target price on the stock. HC Wainwright also issued estimates for Gain Therapeutics' Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.59) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.56) EPS.

Several other equities research analysts have also issued reports on GANX. Chardan Capital reaffirmed a "buy" rating and set a $6.00 price target on shares of Gain Therapeutics in a report on Friday, March 28th. Scotiabank assumed coverage on shares of Gain Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $12.00 price target on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $8.20.

Gain Therapeutics Price Performance

Gain Therapeutics stock traded up $0.01 during trading hours on Monday, reaching $1.80. 72,466 shares of the stock were exchanged, compared to its average volume of 310,559. The company has a market cap of $53.20 million, a P/E ratio of -1.64 and a beta of 0.17. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a twelve month low of $0.89 and a twelve month high of $3.19. The stock has a 50 day moving average of $1.90 and a two-hundred day moving average of $2.00.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). Equities analysts expect that Gain Therapeutics will post -1 EPS for the current fiscal year.

Institutional Investors Weigh In On Gain Therapeutics

A number of institutional investors have recently added to or reduced their stakes in GANX. Benedict Financial Advisors Inc. bought a new stake in shares of Gain Therapeutics in the 4th quarter valued at $35,000. Sprott Inc. bought a new stake in shares of Gain Therapeutics in the 4th quarter valued at $30,000. Jones Financial Companies Lllp boosted its stake in shares of Gain Therapeutics by 83.6% in the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company's stock valued at $212,000 after purchasing an additional 44,750 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Gain Therapeutics in the 4th quarter valued at $198,000. Finally, Northern Trust Corp boosted its stake in shares of Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company's stock valued at $183,000 after purchasing an additional 39,642 shares during the last quarter. 11.97% of the stock is owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.